Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies
To access this article, please choose from the options below
PII: S0960-9776(10)00017-2
doi:10.1016/j.breast.2010.01.015
© 2010 Elsevier Ltd. All rights reserved.
